Business
BridgeBio Pharma to Present Detailed Results from the Phase 3 ATTRibute Study in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) at European Society of Cardiology (ESC) Congress 2023
PALO ALTO, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage
About this update from Bridgebio Pharma, Inc.
[{"type":"text","content":"PALO ALTO, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that detailed Phase 3 results from ATTRibute-CM, its study of acoramidis in transthyretin amyloid cardiomyopathy, or ATTR-CM, will be presented at the European Society of Cardiology (ESC) Congress 2023, taking place in Amsterdam, Netherlands on August 25 - 28, 2023. ATTRibute-CM was designed to study the efficacy and safety of acoramidis, an investigational, next-generation, orally-administered, highly potent, small molecule stabilizer of transthyretin (TTR). BridgeBio will host an investor call with members of the Company’s leadership team as well as Julian Gillmore, M.D., Ph.D., on Monday, August 28 at 8:30 am ET to discuss the results shared at the meeting. In addition to presenting the results from ATTRibute-CM, BridgeBio will also present a moderated poster on the observed near-complete TTR stabilization of acoramidis in patients with variant transthyretin amyloidosis, and will host a satellite symposium to discuss the evolving landscape of ATTR-CM. Oral presentation & moderated poster session details: ATTRibute-CM: Acoramidis (AG10) in patients with transthyretin amyloid cardiomyopathyPresenter: Julian Gillmore, M.D., Ph.D., professor at University College London and head of University College London Centre for Amyloidosis and National Amyloidosis Centre research leadDate/ time: Sunday, August 27 at 11:15 am CESTLocation: ESC Stage, Amsterdam Auditorium, RAI Amsterdam Acoramidis produces near-complete TTR stabilization in blood samples from patients with variant transthyretin amyloidosis that is greater than that achieved with tafamidisPresenter: Alan Xian Ji, Ph.D., Senior Scientist, BridgeBioDate/time: Saturday, August 26 at 5:15 pm CESTLocation: Station 3, RAI Amsterdam Satellite symposium details: Evolving Landscape in ATTR-CM: Clinical Practice and Emerging TreatmentsChair: Francesco Cappelli, M.D., medical director of cardiac surgery at the Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, ItalySpeakers: Marianna Fontana, M.D., director of the Cardiac Magnetic Resonance unit at the University College London and professor of cardiology and honorary consultant cardiologist ...